logo
Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹

Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹

Yahoo6 days ago
Approval is based on the results from phase III KEYNOTE-A18/ENGOT-cx11/GOG-30472
KIRKLAND, QC, July 21, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.1,2 The approval is based on data from the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, which demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients randomized to KEYTRUDA® in combination with CRT compared with patients randomized to placebo plus CRT.3
"The approval of KN-A18 is an important addition to the treatment of gynecological cancers, as it has demonstrated a statistically significant improvement in overall survival and progression-free survival in patients with FIGO 2014 Stage III-IVa," stated Shannon Salvador, Gynecologic Oncologist at the Jewish General Hospital and President of the Society of Gynecologic Oncology of Canada.4 "This recent approval adds another therapeutic option for patients in an important disease space."
"This approval marks a pivotal moment for patients, as it represents the first indication in Canada for KEYTRUDA® in combination with chemoradiotherapy," said André Galarneau, PhD, Executive Director & Vice President, Oncology Business Unit at Merck Canada. "Reaffirming our commitment to cervical cancer, we are eager to continue expanding treatment options for patients impacted by this disease."5
About KEYNOTE-A18 / ENGOT-cx11/GOG-3047KEYNOTE-A18 is a multicenter, randomized, double-blind, placebo-controlled phase III trial (ClinicalTrials.gov, NCT04221945).2 The trial investigated the efficacy of pembrolizumab in combination with CRT (cisplatin and external beam radiation therapy [EBRT] followed by brachytherapy [BT]) for the treatment of patients with locally advanced cervical cancer.1
The trial enrolled 1,060 newly diagnosed patients with locally advanced squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix defined as FIGO 2014 stage IB2 to IIB with positive lymph nodes or stage III to IVA regardless of nodal status.3 There were 599 patients with FIGO 2014 Stage III-IVA.
Randomization was stratified by planned type of EBRT (Intensity modulated radiation therapy [IMRT] or volumetric modulated arc therapy [VMAT] vs. non IMRT and non VMAT), stage at screening of cervical cancer (FIGO 2014 Stage IB2 IIB vs. FIGO 2014 Stage III-IVA), and planned total radiotherapy dose (EBRT + brachytherapy dose of <70 Gy vs. ≥70 Gy as per equivalent dose [EQD2]).1
Patients were randomized (1:1) to one of two treatment arms:
Pembrolizumab 200 mg IV every 3 weeks (5 cycles) concurrent with cisplatin 40 mg/m2 IV weekly (5 cycles, an optional sixth infusion could be administered per local practice) and radiotherapy (EBRT followed by BT), followed by pembrolizumab 400 mg IV every 6 weeks (15 cycles).1,3
Placebo IV every 3 weeks (5 cycles) concurrent with cisplatin 40 mg/m2 IV weekly (5 cycles, an optional sixth infusion could be administered per local practice), and radiotherapy (EBRT followed by BT), followed by placebo IV every 6 weeks (15 cycles).1,3
Treatment continued until RECIST (Response Evaluation Criteria in Solid Tumors) v1.1-defined progression of disease as determined by investigator or unacceptable toxicity.1
Assessment of tumour status was performed every 12 weeks from completion of CRT for the first two years, followed by every 24 weeks in year 3, and then annually. The major efficacy outcome measures were PFS as assessed by investigator according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or histopathologic confirmation, and OS.1
The trial demonstrated statistically significant improvements in both PFS (HR (Hazard Ratio) 0.70; 95% CI (confidence interval): 0.55–0.89; p = 0.002) and OS (HR 0.67; 95% CI: 0.50–0.90; p = 0.004) in the overall population. In an exploratory subgroup analysis for the 459 patients (43%) with FIGO 2014 Stage IB2–IIB disease, the PFS and OS HR estimates were 0.91 (95% CI: 0.63–1.32) and 0.89 (95% CI: 0.55–1.44), respectively, suggesting that the improvements in PFS and OS observed in the overall population were primarily driven by the later-stage subgroup of patients with FIGO 2014 Stage III–IVA disease.
The efficacy results in the exploratory subgroup analysis of 599 patients with FIGO 2014 Stage III-IVA disease showed that pembrolizumab plus CRT demonstrated improvements in PFS (Hazard Ratio (HR) 0.59; 95% CI 0.43, 0.81) and OS (HR 0.58; 95% CI 0.40, 0.85) in the overall population.1
For the FIGO 2014 Stage III-IVA population, the most common treatment-related adverse events (reported in at least 20% of patients) were anemia, nausea, diarrhea, white blood cell count decreased, neutrophil count decreased, vomiting, platelet count decreased, and hypothyroidism.6
For complete information, refer to the KEYTRUDA® product monograph.
About cervical cancer Cervical cancer forms in the cells lining the cervix, which is the lower part of the uterus.7 Despite concerted efforts in screening and prevention across Canada, cervical cancer has become the fastest growing cancer type in females.8,9 In 2024 alone, it was estimated that there were approximately 1,600 women diagnosed with cervical cancer and an estimated 400 deaths as a result of the disease.10
About KEYTRUDA®KEYTRUDA® is an anti-programmed death receptor-1 (anti-PD-1) therapy that works by helping increase the ability of the body's immune system to help detect and fight tumour cells. KEYTRUDA® is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumour cells and healthy cells.11,12,13
KEYTRUDA® was first approved in Canada in 2015 and currently has indications in several disease areas, including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma.14
About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit www.merck.ca and connect with us on LinkedIn @MerckCanada.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
® Merck Sharp & Dohme LLC. Used under license.© 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
CA-NON-04142
References:
1 KEYTRUDA® Product Monograph, page 285-286.2 https://clinicaltrials.gov/study/NCT042219453 The ASCO Post. KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy. https://ascopost.com/issues/october-10-2024/keynote-a18-overall-survival-in-cervical-cancer-improved-by-pembrolizumab-plus-chemoradiotherapy/4 Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial, page 1329. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00317-9/fulltext5 https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426 6 KEYTRUDA® Product Monograph, page 146.7 Canadian Cancer Society. What is cervical cancer? https://cancer.ca/en/cancer-information/cancer-types/cervical/what-is-cervical-cancer 8 Canadian Cancer Statistics 2023, page 22. https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2023-statistics/2023_pdf_en.pdf?rev=7e0c86ef787d425081008ed22377754d&hash=DBD6818195657364D831AF0641C4B45C9 Canadian Cancer Statistics 2023, page 80. https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2023-statistics/2023_pdf_en.pdf?rev=7e0c86ef787d425081008ed22377754d&hash=DBD6818195657364D831AF0641C4B45C10 Canadian Cancer Society. Cervical cancer statistics. https://cancer.ca/en/cancer-information/cancer-types/cervical/statistics11 KEYTRUDA® Product Monograph, page 300.12 KEYTRUDA® Product Monograph, page 188.13 KEYTRUDA® Product Monograph, page 192.14 KEYTRUDA® Product Monograph, pages 1-3.
Media Contacts:
Merck Canada Media Relations1-833-906-3725mediacanada@merck.com
SOURCE Merck
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2025/21/c3580.html
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Upcoming Stock Splits This Week (July 28 to August 1)
Upcoming Stock Splits This Week (July 28 to August 1)

Business Insider

time2 hours ago

  • Business Insider

Upcoming Stock Splits This Week (July 28 to August 1)

These are the upcoming stock splits for the week of July 28 to August 1, based on TipRanks' Stock Splits Calendar. A stock split is a corporate play that boosts the number of shares in circulation by handing out extras to existing shareholders, without changing the company's overall value. This reduces the price per share, making the stock more affordable and often more appealing to retail investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. But not all splits are about broadening appeal. Some companies flip the script with a reverse stock split, consolidating shares to boost the share price while shrinking the total share count. The company's market cap stays the same, but the higher price tag often helps meet listing standards like Nasdaq's minimum price rule, warding off the threat of delisting. Whether the goal is to court investors or stay in the game, these corporate maneuvers often send signals that smart traders are quick to pick up on. Let's take a look at the upcoming stock splits for the week. ChargePoint Holdings (CHPT) – ChargePoint is an electric vehicle (EV) charging infrastructure provider operating an extensive network of chargers and connected services. On July 9, ChargePoint announced a 1‑for‑20 reverse stock split scheduled to become effective on July 28. The split is intended to increase the per-share price and regain compliance with NYSE's minimum bid price requirement, after trading below the $1.00 threshold since January 2025. FOXO Technologies (FOXO) – Developing advanced payment-processing platforms for the dental and medical industries, FOXO is taking strategic action to stay compliant with NYSE American listing standards. On July 17, the board approved a 1‑for‑1.99 reverse stock split effective on July 27, with trading on a split‑adjusted basis starting July 28. Mersana Therapeutics (MRSN) – Mersana is a clinical-stage biotech developing antibody‑drug conjugates (ADCs) targeting cancer. On July 24, it announced a 1‑for‑25 reverse stock split, effective before market open on July 28. The split seeks to increase per‑share price to regain Nasdaq Global Select listing compliance after prolonged depressed stock price. Ikena Oncology (IKNA) – Ikena Oncology, am immuno‑oncology biotech company, received shareholder approval on July 15 for a 1-for-12 reverse stock split, to be implemented at the start of trading on July 28 – the same day it merges with Inmagene Biopharmaceuticals. Upon closing, the combined company will be rebranded as ImageneBio and begin trading on Nasdaq under the ticker symbol IMA. AgriFORCE Growing Systems (AGRI) – AgriFORCE Growing Systems, a Canada-based ag-tech and food systems company listed in the U.S., is going through a 1-for-9 reverse stock split. Shareholders gave the green light back on June 6, and the move will officially take effect when markets opened on July 28. The goal here is to get the share price back above Nasdaq's $1.00 minimum and stay in compliance with listing rules. Velo3D, Inc. (VLDX) – Velo3D, a leading innovator in metal 3D printing technology, is making a move to reposition itself in the market. On July 25, the company announced a 1-for-15 reverse stock split, set to take effect at the start of trading on July 28. To mark the change, Velo3D shares will temporarily trade under the ticker symbol VLDXD for 20 sessions before reverting back to VLDX. Senmiao Technology (AIHS) – Senmiao Technology, a U.S.-listed fintech and auto-finance company based in China, is streamlining its stock structure with a 1-for-10 reverse split. Announced on July 24, and set to take effect on July 29, the move aims to lift its share price to meet Nasdaq's listing standards. Silexion Therapeutics (SLXN) – Israel-based Silexion Therapeutics is a clinical-stage biotechnology company focused on developing personalized cancer vaccines and immuno-oncology therapies. On July 16, Silexion announced a 1-for-15 reverse stock split of its common shares, effective after market close on July 28, with trading on a split-adjusted basis beginning July 29. The reverse split is intended to boost the stock price and regain compliance with Nasdaq's minimum bid price requirement for continued listing. NaaS Technology (NAAS) – NaaS Technology is a China-based provider of EV charging services and software, listed on the Nasdaq. On July 14, the company announced a 1-for-4 reverse ADS split set to take effect on or about July 30. The move aims to lift the ADS price, ensure compliance with Nasdaq's minimum bid requirement, and strengthen its appeal to investors. Biodexa Pharmaceuticals (BDRX) – Biodexa Pharmaceuticals is a UK-based clinical-stage biotechnology company focused on developing treatments for diseases with unmet medical needs, including a Phase 3 trial for familial adenomatous polyposis and a Phase 2a trial for type 1 diabetes. On July 15, the company announced a 1-for-10 reverse ADR split, effective July 31. The goal is to raise the ADR trading price to meet Nasdaq's $1.00 minimum bid price requirement. Yoshiharu Global (YOSH) – Yoshiharu Global is a restaurant operator specializing in Japanese ramen and rolls, primarily located in Southern California and Nevada. On July 18, the board and shareholders approved a 4-for-1 forward stock split, record date July 28, with the additional shares distributed after market close on July 30, and trading on a post-split basis starting July 31. The aim is to increase stock liquidity and investor accessibility, making the shares more appealing to retail investors. TipRanks Stock Splits Calendar.

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Yahoo

time3 hours ago

  • Yahoo

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

Where Will Cameco Stock Be in 3 Years?
Where Will Cameco Stock Be in 3 Years?

Yahoo

time3 hours ago

  • Yahoo

Where Will Cameco Stock Be in 3 Years?

Key Points Cameco's stock recently hit an all-time high. Uranium's soaring commodity price is driving that rally. But it still looks reasonably valued relative to its growth potential. 10 stocks we like better than Cameco › Cameco (NYSE: CCJ), one of the world's top uranium miners, usually isn't a high-growth stock. But over the past three years, its price surged about 250% and now hovers near its all-time high. The S&P 500 only rose 60% during the same period. Let's see why Cameco's stock crushed the market, and if it can keep climbing over the next three years. A look back at Cameco's lost decade Cameco, which is based in Canada, owns uranium mines and mills across Canada, the U.S., and Kazakhstan. It mined roughly 17% of the world's uranium in 2024, making it the second largest uranium miner after Kazatomprom (OTC: NATK.Y), Kazakhstan's national mining company. From 2011 to 2021, Cameco's annual revenue dropped from $2.41 billion to $1.18 billion (in U.S. dollars) without a single year of revenue growth. That decline started after the Fukushima nuclear disaster in March 2011, which triggered a global collapse in uranium prices as many countries cautiously reined in their nuclear energy plans. Uranium's spot price plunged from more than $70 per pound before the Fukushima disaster to less than $20 in 2017, and Cameco was forced to suspend work at its biggest mines and throttle back its production to conserve its cash. Before the uranium market could recover, the COVID pandemic disrupted the market again and forced the company to temporarily shut down more of its mines. The weak Canadian dollar exacerbated that decline because the miner sold its uranium in U.S. dollars. What happened over the past three years? But from 2021 to 2024, Cameco's revenue had a compound annual growth rate (CAGR) of 29% in Canadian dollar terms. Its gross margins also expanded to the double digits over the past two years. Metric 2022 2023 2024 Revenue growth 27% 39% 21% Gross margin 0.1% 21.7% 25% Data source: Cameco (all figures in Canadian dollar terms). That robust recovery was driven by uranium's spot prices, which soared from $29.63 in January 2021 to $78.50 this June. That rally prompted Cameco to restart its mining operations at McArthur River in Australia and Key Lake in the Canadian province of Saskatchewan in 2022 after being suspended in 2018. It also partnered with Brookfield Asset Management to acquire the nuclear power plant designer and builder Westinghouse Electric in late 2023. Its new 49% stake in Westinghouse should offset the volatility of its core mining business and make it the top uranium supplier for those plants. Several catalysts drove uranium's price higher over the past few years. The global supply shrank as Cameco and Kazatomprom curbed their production, but the demand rose as more countries initiated new nuclear energy plans and resumed their idled projects. Other global challenges are keeping uranium prices elevated. Russia, which was a major exporter of enriched uranium products and services to the U.S. and Europe, was hit by sanctions and export bans after its invasion of Ukraine in early 2022. Kazatomprom's supply chain issues and a coup in Niger (another key producer of uranium) in 2023 further reduced the global supply while driving more nuclear energy companies to buy their uranium from Cameco. What will happen to Cameco over the next three years? The bulls expect uranium's price to soar even higher as the market's demand continues to outstrip its available supply. The rapid growth of the cloud and AI data center markets -- which are driving more companies to consider using next-gen nuclear energy solutions like small modular reactors (SMRs) and microreactors -- could amplify those gains. Looking ahead, Cameco's 49% stake in Global Laser Enrichment (GLE) -- its uranium enrichment joint venture with Silex -- could transform it into a one-stop shop for nuclear power as it integrates those uranium enrichment capabilities into its core mining and conversion businesses. The International Atomic Energy Agency (IAEA) expects the world's nuclear capacity to expand by up to 2.5 times from 2024 to 2050, so Cameco could still have plenty of room to grow over the next few decades. From 2024 to 2027, analysts expect Cameco's revenue to have a CAGR of 8% (in Canadian dollar terms) as its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) have a CAGR of 16%. Its growth should cool off as it laps the big spike in uranium spot prices, the restarting of its mines, and its investment in Westinghouse Electric, but it still looks reasonably valued at 25 times this year's adjusted EBITDA. So even though Cameco's stock is trading near its all-time high, it could rise even higher over the next three years. Should you invest $1,000 in Cameco right now? Before you buy stock in Cameco, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Cameco wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Leo Sun has no position in any of the stocks mentioned. The Motley Fool recommends Brookfield Asset Management and Cameco. The Motley Fool has a disclosure policy. Where Will Cameco Stock Be in 3 Years? was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store